BeyondSpring Pharmaceuticals

Executive Summary

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies. Its lead asset, Plinabulin, is a first-in-class immune-modulating small molecule designed to treat multiple cancer indications, including non-small cell lung cancer (NSCLC) and chemotherapy-induced neutropenia (CIN). The company is advancing Plinabulin through Phase 3 clinical trials in both the United States and China, with potential to address significant unmet medical needs. BeyondSpring's pipeline also includes earlier-stage programs targeting various solid tumors. The company has established a strong intellectual property portfolio and strategic partnerships to support global development and commercialization. With a seasoned management team and a focus on patients, BeyondSpring is positioned to deliver transformative therapies to cancer patients worldwide.

Upcoming Catalysts (preview)

• Q2 2025Phase 3 Plinabulin NSCLC Overall Survival Data60% success
• Q4 2025NDA Submission for Plinabulin in CIN70% success
• H1 2026Potential Strategic Partnership for Asian Markets50% success